Canine pancreatitis injectable lands U.S. distributionMay 18, 2023Panoquell-CA1’s active ingredient, fuzapladib sodium, has been approved for canine use in Japan since 2018.
Education Center - SponsoredVector-Borne Disease Coming to a Neighborhood Near You: Which Tests to Reach For, and Why?by • AntechWhether it’s a screening to identify exposure to tick-borne pathogens, or a broad molecular diagnostic panel to help with acute disease detection or confirm the presence of genetic material, these options empower veterinary teams, guide treatment, and support antimicrobial stewardship.
Canine pancreatitis injectable OKed by FDANovember 21, 2022Panoquell-CA1 has been granted conditional approval from the U.S. Food and Drug Administration (FDA) for the management of clinical signs associated with acute onset of pancreatitis in canines.
Clinical trial aims to treat canine pancreatitisFebruary 6, 2020ISK and AlcheraBio are seeking clinics to serve as clinical investigator sites to explore treatment options for patients diagnosed with acute canine pancreatitis (ACP).
